CVE-2023-43991

CVE-2023-43991 is a medium-severity vulnerability in Linecorp Line with a CVSS 3.x base score of 5.4. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low.

Key facts

Description

An issue in PRIMA CLINIC mini-app on Line v13.6.1 allows attackers to send crafted malicious notifications via leakage of the channel access token.

Frequently asked questions

What is CVE-2023-43991?
An issue in PRIMA CLINIC mini-app on Line v13.6.1 allows attackers to send crafted malicious notifications via leakage of the channel access token.
How severe is CVE-2023-43991?
CVE-2023-43991 has a CVSS 3.x base score of 5.4, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is low, integrity low, and availability none.
Is CVE-2023-43991 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (31st percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-43991?
CVE-2023-43991 affects Linecorp Line. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-43991?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
Does CVE-2023-43991 have an EU (EUVD) identifier?
Yes. CVE-2023-43991 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2023-48350.
When was CVE-2023-43991 published?
CVE-2023-43991 was published on 2024-01-24 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Linecorp Line

All CVEs affecting Linecorp Line →